Drug and vaccine manufacturing giant Pfizer Inc. (PFE) is facing losses due to the company's charges due to its difficulty concerning COVID antiviral treatment Paxlovid and COVID vaccine.
PFE recently reported its third-quarter results, posting a $13.23 billion revenue, indicating a 42% year-over-year decline and missing the $13.34 billion expected. However, the company also reported an adjusted loss per share of 17 cents, narrower than the 34 cents expected.
